Shionogi Revenue and Competitors

Florham Park, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Shionogi's estimated annual revenue is currently $119.4M per year.(i)
  • Shionogi's estimated revenue per employee is $201,000

Employee Data

  • Shionogi has 594 Employees.(i)
  • Shionogi grew their employee count by 3% last year.

Shionogi's People

NameTitleEmail/Phone
1
Global VP Clinical OperationsReveal Email/Phone
2
VP Hospital MarketingReveal Email/Phone
3
SVP and General CounselReveal Email/Phone
4
VP FinanceReveal Email/Phone
5
VP Information TechnologyReveal Email/Phone
6
VP, ComplianceReveal Email/Phone
7
Corporate OfficerReveal Email/Phone
8
EVP and Chief Global Operations OfficerReveal Email/Phone
9
VP, Government AffairsReveal Email/Phone
10
VP ComplianceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Shionogi?

About Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease. It's Time to Revolutionize Medicine Again More than 23,000 men, women and children in the U.S. die every year from antibiotic-resistant infections1 while over 4,000 Americans perish from influenza.2 In addition, over 100 million suffer from chronic pain3 and 3.9 million adults in the U.S. are diagnosed with liver disease.4 Shionogi's mission is to supply the best possible medicines to protect the health and well-being of the patients we serve. With over 50 years of anti-infective research experience, Shionogi has helped to revolutionize the development of antibacterial and antiviral treatments. As bacteria, pathogens and other viruses adapt to resist existing treatmentscausing millions of untreatable infections around the worldShionogi is pursuing the development of novel treatments to combat this evolving threat. Shionogi, both itself and through innovative alliances, is also pursuing the development of new treatments in other areas of high medical need, including inflammatory pain, neuropathic pain, Alzheimer's disease and ADHD. At Shionogi Inc., were intensely focused on developing and commercializing the scientific breakthroughs emerging from our research laboratories in Japan as well as discoveries of our strategic alliance partners. We couple our innovative discovery base with capabilities to advance drug candidates rapidly from lab to clinic to patient, forming, where appropriate, bold new partnerships to accelerate and amplify the availability of these new medications to patients around the world.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

594

Number of Employees

$119.4M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shionogi News

2022-04-20 - Shionogi's Oral Antiviral S-217622 Rapidly Clears COVID-19 ...

Today, Shionogi & Co., Ltd. announced positive trial data for their once-daily oral COVID-19 antiviral, S-217622. The studies examined the...

2022-04-19 - Shionogi in talks with U.S. to supply COVID oral drug

OSAKA -- Japanese drugmaker Shionogi & Co. said Friday that it has entered talks with the U.S. government to supply its oral medication for...

2022-04-17 - U.S. in talks with Japan's Shionogi to buy new COVID-19 pill

In its quest to build up its stockpile of COVID-19 drugs, the U.S. government has held talks with Japanese drugmaker Shionogi & Co. about...

2009-03-09 - Victory Pharma Raises $45M

San Diego-based Victory Pharma has raised $45M in an equity financing round, the firm said Monday. The round was led by Essex Woodlands Health Ventures, and also included prior investor Ampersand Ventures. According to Victory Pharma, Scott Barry of Essex Partners joins its board along with the ...

2009-03-09 - Victory Pharma Announces US$45 Million Equity Financing

Mar 09 2009 SAN DIEGO, California—Victory Pharma, Inc. (“Victory” or “the Company”), a privately held specialty pharmaceutical company, today announced that it has closed on a US$45 million equity financing facility led by Essex Woodlands Health Ventures (“Essex”). Ampersand Ventures, an existi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$200M6531%N/A
#2
$163.5M7308%N/A
#3
$423.4M1205-2%N/A
#4
$1063M3099-8%N/A
#5
$4321.2M10120N/AN/A